Tag:

Genzyme

Latest Headlines

Latest Headlines

D-Day for Sanofi MS drug Aubagio as deep R&D cuts loom

This is a big day for Sanofi and Genzyme, its biologics arm in Boston. The FDA is slated to make a final ruling on Aubagio (teriflunomide), its new oral treatment for multiple sclerosis.

Sanofi plans to buy back $152M in Genzyme CVRs

The move is seen as a sign that Sanofi is confident that the multiple sclerosis drug Lemtrada will be as lucrative as hoped.

Sanofi recalls 9 lots of Genzyme transplant drug

Genzyme is pulling 9 lots of its kidney transplant drug Thymoglobulin after one lot failed a stability test. The company, which is Sanofi's ($SNY) U.S.-based rare disease division, pulled all lots made with raw material suspected to be the "root cause" of the potential shelf-life issue.

Sanofi's Genzyme recalls transplant drug after stability test failure

Sanofi ($SNY) is reporting another manufacturing problem, this time at one of the plants operated by its Genzyme subsidiary, causing it to recall a transplant-rejection drug.

Sanofi hits a speed bump on blockbuster Lemtrada application

Just weeks after Genzyme filed its application for Lemtrada as a new treatment for multiple sclerosis, regulators have handed the NDA back, telling the biologics arm of Sanofi that it needs to complete a rewrite before they can properly assess it.

Sanofi pulls Campath to clear way for higher-priced Lemtrada

The speculation about Genzyme's Campath is over. The company, now a unit of Sanofi, is pulling the plug. Why? To prepare the way for Lemtrada, a multiple sclerosis treatment that is, essentially, Campath by another name.

FDA has four big drug decisions lined up

The next 5 or 6 weeks look big for potential approvals of new drugs.

Isis Pharmaceuticals' 'anti-sense' drug combats muscular dystrophy in mice

A potential new Isis Pharmaceuticals ($ISIS) "anti-sense" drug helped restore normal muscle function in mice suffering from a form of muscular dystrophy. Credit new research spearheaded by Genzyme and the University of Rochester Medical Center with achieving the breakthrough.

Teva accuses Genzyme of stealing Copaxone reps

Stop, thief! That's what Teva Pharmaceuticals is saying to Genzyme, in a dispute over sales reps. It seems a former Teva sales manager who defected to Genzyme is accused of poaching his former co-workers.

Sanofi sets out to reinvent itself in Genzyme's biotech image

Genzyme CEO David Meeker must be smiling today. Sanofi CEO Chris Viehbacher is taking a page out of the Roche reinvention playbook. Just as Roche has restructured its Big Pharma R&D efforts around Genentech, Sanofi's Viehbacher sees its research ops being transformed by Genzyme's biotech example.